top headlines
Almirall has received a positive CHMP opinion recommending an expanded [...]
ProMIS Neurosciences has licensed Ossianix’s TXP1 technology to improve antibody [...]
Movers & Shakers
sponsored content
Other news
Oncoinvent has reported no treatment-related serious adverse events in the [...]
Enterprise Therapeutics has secured European orphan medicinal product designation for [...]
BioVie has reported two biomarker-defined Long COVID subgroups in its [...]
Nuclera and University of Cambridge researchers have demonstrated a four-day [...]
Lonza has signed its first license agreement for its NeuroPortal [...]
Neurizon Therapeutics has advanced its Phase 2/3 HEALEY ALS Platform [...]









